{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T23:55:30Z","timestamp":1793058930075,"version":"4.5.0"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2022,9,13]],"date-time":"2022-09-13T00:00:00Z","timestamp":1663027200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,9,13]],"date-time":"2022-09-13T00:00:00Z","timestamp":1663027200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100016198","name":"Idorsia Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100016198","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs Aging"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1007\/s40266-022-00977-4","type":"journal-article","created":{"date-parts":[[2022,9,13]],"date-time":"2022-09-13T03:07:07Z","timestamp":1663038427000},"page":"795-810","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":53,"title":["Efficacy and Safety of Daridorexant in Older and Younger Adults with Insomnia Disorder: A Secondary Analysis of a Randomised Placebo-Controlled Trial"],"prefix":"10.1007","volume":"39","clinical-trial-number":[{"clinical-trial-number":"nct03545191","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Ingo","family":"Fietze","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio L. A.","family":"Bassetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David W.","family":"Mayleben","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Pain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dalma","family":"Seboek Kinter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5035-7858","authenticated-orcid":false,"given":"William V.","family":"McCall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,9,13]]},"reference":[{"key":"977_CR1","unstructured":"United Nations Department of Economics and Social Affairs Population Division. World population ageing 2019. Available from: https:\/\/www.un.org\/en\/development\/desa\/population\/publications\/pdf\/ageing\/WorldPopulationAgeing2019-Highlights.pdf. Accessed 30 Aug 2022."},{"key":"977_CR2","doi-asserted-by":"crossref","DOI":"10.1176\/appi.books.9780890425596","volume-title":"Diagnostic and statistical manual of mental disorders","author":"American Psychiatric Association","year":"2013","unstructured":"American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Washington, DC: American Psychiatric Publishing; 2013.","edition":"5"},{"issue":"6","key":"977_CR3","first-page":"916","volume":"73","author":"E Ito","year":"2015","unstructured":"Ito E, Inoue Y. The international classification of sleep disorders, third edition. Am Acad Sleep Med. 2015;73(6):916\u201323.","journal-title":"Am Acad Sleep Med."},{"key":"977_CR4","doi-asserted-by":"publisher","first-page":"527","DOI":"10.3389\/fpsyg.2020.00527","volume":"11","author":"I Bjor\u00f8y","year":"2020","unstructured":"Bjor\u00f8y I, J\u00f8rgensen VA, Pallesen S, Bjorvatn B. The prevalence of insomnia subtypes in relation to demographic characteristics, anxiety, depression, alcohol consumption and use of hypnotics. Front Psychol. 2020;11:527. https:\/\/doi.org\/10.3389\/fpsyg.2020.00527.","journal-title":"Front Psychol"},{"issue":"2","key":"977_CR5","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.sleep.2013.10.009","volume":"15","author":"S Pallesen","year":"2014","unstructured":"Pallesen S, Sivertsen B, Nordhus IH, Bjorvatn B. A 10-year trend of insomnia prevalence in the adult Norwegian population. Sleep Med. 2014;15(2):173\u20139. https:\/\/doi.org\/10.1016\/j.sleep.2013.10.009.","journal-title":"Sleep Med"},{"issue":"9","key":"977_CR6","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1177\/070674371105600905","volume":"56","author":"CM Morin","year":"2011","unstructured":"Morin CM, LeBlanc M, B\u00e9langer L, Ivers H, M\u00e9rette C, Savard J. Prevalence of insomnia and its treatment in Canada. Can J Psychiatry. 2011;56(9):540\u20138. https:\/\/doi.org\/10.1177\/070674371105600905.","journal-title":"Can J Psychiatry"},{"key":"977_CR7","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s12877-015-0068-2","volume":"15","author":"AC Hayley","year":"2015","unstructured":"Hayley AC, Williams LJ, Kennedy GA, Holloway KL, Berk M, Brennan-Olsen SL, et al. Excessive daytime sleepiness and falls among older men and women: cross-sectional examination of a population-based sample. BMC Geriatr. 2015;15:74. https:\/\/doi.org\/10.1186\/s12877-015-0068-2.","journal-title":"BMC Geriatr"},{"issue":"9","key":"977_CR8","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.5665\/sleep.2070","volume":"35","author":"I Jaussent","year":"2012","unstructured":"Jaussent I, Bouyer J, Ancelin ML, Berr C, Foubert-Samier A, Ritchie K, et al. Excessive sleepiness is predictive of cognitive decline in the elderly. Sleep. 2012;35(9):1201\u20137. https:\/\/doi.org\/10.5665\/sleep.2070.","journal-title":"Sleep"},{"issue":"9","key":"977_CR9","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1111\/j.1532-5415.2008.01846.x","volume":"56","author":"TT Dam","year":"2008","unstructured":"Dam TT, Ewing S, Ancoli-Israel S, Ensrud K, Redline S, Stone K. Association between sleep and physical function in older men: the osteoporotic fractures in men sleep study. J Am Geriatr Soc. 2008;56(9):1665\u201373. https:\/\/doi.org\/10.1111\/j.1532-5415.2008.01846.x.","journal-title":"J Am Geriatr Soc"},{"key":"977_CR10","doi-asserted-by":"publisher","first-page":"329","DOI":"10.2147\/nss.S299833","volume":"13","author":"D Kirshner","year":"2021","unstructured":"Kirshner D, Kizony R, Gil E, Asraf K, Krasovsky T, Haimov I, et al. Why do they fall? The impact of insomnia on gait of older adults: a case-control study. Nat Sci Sleep. 2021;13:329\u201338. https:\/\/doi.org\/10.2147\/nss.S299833.","journal-title":"Nat Sci Sleep."},{"issue":"Suppl. 2","key":"977_CR11","first-page":"S366","volume":"22","author":"DJ Foley","year":"1999","unstructured":"Foley DJ, Monjan A, Simonsick EM, Wallace RB, Blazer DG. Incidence and remission of insomnia among elderly adults: an epidemiologic study of 6,800 persons over three years. Sleep. 1999;22(Suppl. 2):S366\u201372.","journal-title":"Sleep"},{"issue":"3","key":"977_CR12","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1111\/psyg.12319","volume":"18","author":"KK Gulia","year":"2018","unstructured":"Gulia KK, Kumar VM. Sleep disorders in the elderly: a growing challenge. Psychogeriatrics. 2018;18(3):155\u201365. https:\/\/doi.org\/10.1111\/psyg.12319.","journal-title":"Psychogeriatrics"},{"issue":"8","key":"977_CR13","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1001\/archinte.1992.00400200070012","volume":"152","author":"ME Klink","year":"1992","unstructured":"Klink ME, Quan SF, Kaltenborn WT, Lebowitz MD. Risk factors associated with complaints of insomnia in a general adult population: influence of previous complaints of insomnia. Arch Intern Med. 1992;152(8):1634\u20137.","journal-title":"Arch Intern Med"},{"issue":"6","key":"977_CR14","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.5664\/jcsm.7172","volume":"14","author":"D Patel","year":"2018","unstructured":"Patel D, Steinberg J, Patel P. Insomnia in the elderly: a review. J Clin Sleep Med. 2018;14(6):1017\u201324. https:\/\/doi.org\/10.5664\/jcsm.7172.","journal-title":"J Clin Sleep Med"},{"issue":"2","key":"977_CR15","doi-asserted-by":"publisher","first-page":"255","DOI":"10.5664\/jcsm.8986","volume":"17","author":"JD Edinger","year":"2021","unstructured":"Edinger JD, Arnedt JT, Bertisch SM, Carney CE, Harrington JJ, Lichstein KL, et al. Behavioral and psychological treatments for chronic insomnia disorder in adults: an American Academy of Sleep Medicine clinical practice guideline. J Clin Sleep Med. 2021;17(2):255\u201362. https:\/\/doi.org\/10.5664\/jcsm.8986.","journal-title":"J Clin Sleep Med"},{"issue":"2","key":"977_CR16","doi-asserted-by":"publisher","first-page":"125","DOI":"10.7326\/m15-2175","volume":"165","author":"A Qaseem","year":"2016","unstructured":"Qaseem A, Kansagara D, Forciea MA, Cooke M, Denberg TD. Management of chronic insomnia disorder in adults: a clinical practice guideline from the American College of Physicians. Ann Intern Med. 2016;165(2):125\u201333. https:\/\/doi.org\/10.7326\/m15-2175.","journal-title":"Ann Intern Med"},{"issue":"6","key":"977_CR17","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1016\/j.jagp.2020.10.011","volume":"29","author":"JM Flaxer","year":"2021","unstructured":"Flaxer JM, Heyer A, Francois D. Evidenced-based review and evaluation of clinical significance: nonpharmacological and pharmacological treatment of insomnia in the elderly. Am J Geriatr Psychiatry. 2021;29(6):585\u2013603. https:\/\/doi.org\/10.1016\/j.jagp.2020.10.011.","journal-title":"Am J Geriatr Psychiatry"},{"issue":"6","key":"977_CR18","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1007\/s11606-018-4390-1","volume":"33","author":"E Koffel","year":"2018","unstructured":"Koffel E, Bramoweth AD, Ulmer CS. Increasing access to and utilization of cognitive behavioral therapy for insomnia (CBT-I): a narrative review. J Gen Intern Med. 2018;33(6):955\u201362. https:\/\/doi.org\/10.1007\/s11606-018-4390-1.","journal-title":"J Gen Intern Med"},{"issue":"1","key":"977_CR19","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1186\/s13643-019-1163-9","volume":"8","author":"P Rios","year":"2019","unstructured":"Rios P, Cardoso R, Morra D, Nincic V, Goodarzi Z, Farah B, et al. Comparative effectiveness and safety of pharmacological and non-pharmacological interventions for insomnia: an overview of reviews. Syst Rev. 2019;8(1):281. https:\/\/doi.org\/10.1186\/s13643-019-1163-9.","journal-title":"Syst Rev"},{"issue":"1","key":"977_CR20","first-page":"29","volume":"96","author":"E Matheson","year":"2017","unstructured":"Matheson E, Hainer BL. Insomnia: pharmacologic therapy. Am Fam Physician. 2017;96(1):29\u201335.","journal-title":"Am Fam Physician"},{"issue":"1","key":"977_CR21","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1186\/s12875-022-01707-w","volume":"23","author":"M Tanielian","year":"2022","unstructured":"Tanielian M, Antoun J, Sidani M, Halabi A, Hoballah M, Hawatian K, et al. Sleep pattern and predictors of daily versus as-needed hypnotics use in middle-aged and older adults with insomnia. BMC Prim Care. 2022;23(1):98. https:\/\/doi.org\/10.1186\/s12875-022-01707-w.","journal-title":"BMC Prim Care."},{"key":"977_CR22","doi-asserted-by":"publisher","first-page":"117957351877067","DOI":"10.1177\/1179573518770672","volume":"10","author":"DN Neubauer","year":"2018","unstructured":"Neubauer DN, Pandi-Perumal SR, Spence DW, Buttoo K, Monti JM. Pharmacotherapy of insomnia. J Cent Nerv Syst Dis. 2018;10:1179573518770672. https:\/\/doi.org\/10.1177\/1179573518770672.","journal-title":"J Cent Nerv Syst Dis."},{"issue":"7","key":"977_CR23","doi-asserted-by":"publisher","first-page":"601","DOI":"10.2174\/138920011796504527","volume":"12","author":"S Shi","year":"2011","unstructured":"Shi S, Klotz U. Age-related changes in pharmacokinetics. Curr Drug Metab. 2011;12(7):601\u201310. https:\/\/doi.org\/10.2174\/138920011796504527.","journal-title":"Curr Drug Metab"},{"issue":"3","key":"977_CR24","doi-asserted-by":"publisher","first-page":"23","DOI":"10.37901\/jcphp18-00022","volume":"66","author":"KL Nguyen","year":"2020","unstructured":"Nguyen KL, Watanabe JH. Association between sleep medications and falls and fall-related worries in community-dwelling older adults in the United States. J Contemp Pharm Pract. 2020;66(3):23\u201332. https:\/\/doi.org\/10.37901\/jcphp18-00022.","journal-title":"J Contemp Pharm Pract."},{"issue":"4","key":"977_CR25","doi-asserted-by":"publisher","first-page":"219","DOI":"10.3961\/jpmph.2012.45.4.219","volume":"45","author":"D-Y Kang","year":"2012","unstructured":"Kang D-Y, Park S, Rhee C-W, Kim Y-J, Choi N-K, Lee J, et al. Zolpidem use and risk of fracture in elderly insomnia patients. J Prev Med Public Health. 2012;45(4):219. https:\/\/doi.org\/10.3961\/jpmph.2012.45.4.219.","journal-title":"J Prev Med Public Health"},{"issue":"10","key":"977_CR26","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1136\/jech-2011-200314","volume":"66","author":"J Gallacher","year":"2012","unstructured":"Gallacher J, Elwood P, Pickering J, Bayer A, Fish M, Ben-Shlomo Y. Benzodiazepine use and risk of dementia: evidence from the Caerphilly Prospective Study (CaPS). J Epidemiol Community Health. 2012;66(10):869\u201373. https:\/\/doi.org\/10.1136\/jech-2011-200314.","journal-title":"J Epidemiol Community Health"},{"issue":"2","key":"977_CR27","doi-asserted-by":"publisher","first-page":"125","DOI":"10.2165\/11539050-000000000-00000","volume":"34","author":"T Dassanayake","year":"2011","unstructured":"Dassanayake T, Michie P, Carter G, Jones A. Effects of benzodiazepines, antidepressants and opioids on driving: a systematic review and meta-analysis of epidemiological and experimental evidence. Drug Saf. 2011;34(2):125\u201356. https:\/\/doi.org\/10.2165\/11539050-000000000-00000.","journal-title":"Drug Saf"},{"key":"977_CR28","doi-asserted-by":"publisher","unstructured":"American Geriatrics Society 2019 updated AGS Beers Criteria\u00ae for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2019;67(4):674\u201394. https:\/\/doi.org\/10.1111\/jgs.15767.","DOI":"10.1111\/jgs.15767"},{"issue":"2","key":"977_CR29","doi-asserted-by":"publisher","first-page":"307","DOI":"10.5664\/jcsm.6470","volume":"13","author":"MJ Sateia","year":"2017","unstructured":"Sateia MJ, Buysse DJ, Krystal AD, Neubauer DN, Heald JL. Clinical practice guideline for the pharmacologic treatment of chronic insomnia in adults: an American Academy of Sleep Medicine clinical practice guideline. J Clin Sleep Med. 2017;13(2):307\u201349. https:\/\/doi.org\/10.5664\/jcsm.6470.","journal-title":"J Clin Sleep Med"},{"issue":"3","key":"977_CR30","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1038\/nrn2092","volume":"8","author":"T Sakurai","year":"2007","unstructured":"Sakurai T. The neural circuit of orexin (hypocretin): maintaining sleep and wakefulness. Nat Rev Neurosci. 2007;8(3):171\u201381. https:\/\/doi.org\/10.1038\/nrn2092.","journal-title":"Nat Rev Neurosci"},{"issue":"5","key":"977_CR31","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1007\/s40265-022-01699-y","volume":"82","author":"A Markham","year":"2022","unstructured":"Markham A. Daridorexant: first approval. Drugs. 2022;82(5):601\u20137. https:\/\/doi.org\/10.1007\/s40265-022-01699-y.","journal-title":"Drugs"},{"issue":"3","key":"977_CR32","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1124\/jpet.117.241596","volume":"362","author":"A Treiber","year":"2017","unstructured":"Treiber A, de Kanter R, Roch C, Gatfield J, Boss C, von Raumer M, et al. The use of physiology-based pharmacokinetic and pharmacodynamic modeling in the discovery of the dual orexin receptor antagonist ACT-541468. J Pharmacol Exp Ther. 2017;362(3):489\u2013503. https:\/\/doi.org\/10.1124\/jpet.117.241596.","journal-title":"J Pharmacol Exp Ther"},{"issue":"7","key":"977_CR33","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1016\/j.euroneuro.2019.05.009","volume":"29","author":"C Muehlan","year":"2019","unstructured":"Muehlan C, Brooks S, Zuiker R, van Gerven J, Dingemanse J. Multiple-dose clinical pharmacology of ACT-541468, a novel dual orexin receptor antagonist, following repeated-dose morning and evening administration. Eur Neuropsychopharmacol. 2019;29(7):847\u201357. https:\/\/doi.org\/10.1016\/j.euroneuro.2019.05.009.","journal-title":"Eur Neuropsychopharmacol"},{"issue":"5","key":"977_CR34","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1002\/cpt.1046","volume":"104","author":"C Muehlan","year":"2018","unstructured":"Muehlan C, Heuberger J, Juif PE, Croft M, van Gerven J, Dingemanse J. Accelerated development of the dual orexin receptor antagonist ACT-541468: integration of a microtracer in a first-in-human study. Clin Pharmacol Ther. 2018;104(5):1022\u20139. https:\/\/doi.org\/10.1002\/cpt.1046.","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"977_CR35","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/S1474-4422(21)00436-1","volume":"21","author":"E Mignot","year":"2022","unstructured":"Mignot E, Mayleben D, Fietze I, Leger D, Zammit G, Bassetti CLA, et al. Safety and efficacy of daridorexant in patients with insomnia disorder: results from two multicentre, randomised, double-blind, placebo-controlled, phase 3 trials. Lancet Neurol. 2022;21(2):125\u201339. https:\/\/doi.org\/10.1016\/S1474-4422(21)00436-1.","journal-title":"Lancet Neurol"},{"key":"977_CR36","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1007\/s40271-020-00474-z","volume":"14","author":"S Hudgens","year":"2020","unstructured":"Hudgens S, Phillips-Beyer A, Newton L, Seboek Kinter D, Benes H. Development and validation of the Insomnia Daytime Symptoms and Impacts Questionnaire (IDSIQ). Patient. 2020;14:249\u201368. https:\/\/doi.org\/10.1007\/s40271-020-00474-z.","journal-title":"Patient"},{"issue":"21","key":"977_CR37","doi-asserted-by":"publisher","first-page":"e2222","DOI":"10.1212\/WNL.0000000000009475","volume":"94","author":"G Zammit","year":"2020","unstructured":"Zammit G, Dauvilliers Y, Pain S, Sebok Kinter D, Mansour Y, Kunz D. Daridorexant, a new dual orexin receptor antagonist, in elderly subjects with insomnia disorder. Neurology. 2020;94(21):e2222\u201332. https:\/\/doi.org\/10.1212\/WNL.0000000000009475.","journal-title":"Neurology"},{"key":"977_CR38","doi-asserted-by":"crossref","unstructured":"Kunz D, Benes H, Garcia-Borreguero D, Dauvilliers Y, Plazzi G, Sassi-Sayadi M, et al. Long-term safety and efficacy of daridorexant in patients with insomnia disorder. In: Presented at World Sleep; 11-16 March, 2022: abstract 2145.","DOI":"10.1016\/j.sleep.2022.05.356"},{"issue":"10","key":"977_CR39","doi-asserted-by":"publisher","first-page":"2487","DOI":"10.1185\/03007990903167415","volume":"25","author":"M Yang","year":"2009","unstructured":"Yang M, Morin CM, Schaefer K, Wallenstein GV. Interpreting score differences in the Insomnia Severity Index: using health-related outcomes to define the minimally important difference. Curr Med Res Opin. 2009;25(10):2487\u201394. https:\/\/doi.org\/10.1185\/03007990903167415.","journal-title":"Curr Med Res Opin"},{"issue":"1","key":"977_CR40","doi-asserted-by":"publisher","first-page":"9","DOI":"10.4088\/pcc.v06n0104","volume":"6","author":"WV McCall","year":"2004","unstructured":"McCall WV. Sleep in the elderly: burden, diagnosis, and treatment. Prim Care Companion J Clin Psychiatry. 2004;6(1):9\u201320. https:\/\/doi.org\/10.4088\/pcc.v06n0104.","journal-title":"Prim Care Companion J Clin Psychiatry."},{"issue":"6583","key":"977_CR41","doi-asserted-by":"publisher","DOI":"10.1126\/science.abh3021","volume":"375","author":"SB Li","year":"2022","unstructured":"Li SB, Damonte VM, Chen C, Wang GX, Kebschull JM, Yamaguchi H, et al. Hyperexcitable arousal circuits drive sleep instability during aging. Science. 2022;375(6583): eabh3021. https:\/\/doi.org\/10.1126\/science.abh3021.","journal-title":"Science"},{"issue":"1","key":"977_CR42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jsmc.2017.09.001","volume":"13","author":"J Li","year":"2018","unstructured":"Li J, Vitiello MV, Gooneratne NS. Sleep in normal aging. Sleep Med Clin. 2018;13(1):1\u201311. https:\/\/doi.org\/10.1016\/j.jsmc.2017.09.001.","journal-title":"Sleep Med Clin"},{"issue":"4","key":"977_CR43","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/0197-4580(82)90020-3","volume":"3","author":"MA Carskadon","year":"1982","unstructured":"Carskadon MA, Brown ED, Dement WC. Sleep fragmentation in the elderly: relationship to daytime sleep tendency. Neurobiol Aging. 1982;3(4):321\u20137. https:\/\/doi.org\/10.1016\/0197-4580(82)90020-3.","journal-title":"Neurobiol Aging"},{"issue":"1","key":"977_CR44","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.neuron.2017.02.004","volume":"94","author":"BA Mander","year":"2017","unstructured":"Mander BA, Winer JR, Walker MP. Sleep and human aging. Neuron. 2017;94(1):19\u201336. https:\/\/doi.org\/10.1016\/j.neuron.2017.02.004.","journal-title":"Neuron"},{"issue":"3","key":"977_CR45","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1177\/0269881119882854","volume":"34","author":"C Muehlan","year":"2020","unstructured":"Muehlan C, Boehler M, Brooks S, Zuiker R, van Gerven J, Dingemanse J. Clinical pharmacology of the dual orexin receptor antagonist ACT-541468 in elderly subjects: exploration of pharmacokinetics, pharmacodynamics and tolerability following single-dose morning and repeated-dose evening administration. J Psychopharmacol. 2020;34(3):326\u201335. https:\/\/doi.org\/10.1177\/0269881119882854.","journal-title":"J Psychopharmacol"},{"issue":"5","key":"977_CR46","doi-asserted-by":"publisher","first-page":"297","DOI":"10.2165\/00003088-200847050-00002","volume":"47","author":"JM Butler","year":"2008","unstructured":"Butler JM, Begg EJ. Free drug metabolic clearance in elderly people. Clin Pharmacokinet. 2008;47(5):297\u2013321. https:\/\/doi.org\/10.2165\/00003088-200847050-00002.","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"977_CR47","doi-asserted-by":"publisher","first-page":"33","DOI":"10.2165\/00003088-200544010-00002","volume":"44","author":"MM Cotreau","year":"2005","unstructured":"Cotreau MM, von Moltke LL, Greenblatt DJ. The influence of age and sex on the clearance of cytochrome P450 3A substrates. Clin Pharmacokinet. 2005;44(1):33\u201360. https:\/\/doi.org\/10.2165\/00003088-200544010-00002.","journal-title":"Clin Pharmacokinet"},{"key":"977_CR48","doi-asserted-by":"publisher","first-page":"e2222","DOI":"10.1212\/wnl.0000000000009475","volume":"94","author":"G Zammit","year":"2020","unstructured":"Zammit G, Dauvilliers Y, Pain S, Sebok Kinter D, Mansour Y, Kunz D. Daridorexant, a new dual orexin receptor antagonist, in elderly subjects with insomnia disorder. Neurology. 2020;94:e2222\u201332. https:\/\/doi.org\/10.1212\/wnl.0000000000009475.","journal-title":"Neurology"},{"issue":"3","key":"977_CR49","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1002\/ana.25680","volume":"87","author":"Y Dauvilliers","year":"2020","unstructured":"Dauvilliers Y, Zammit G, Fietze I, Mayleben D, Seboek Kinter D, Pain S, et al. Daridorexant, a new dual orexin receptor antagonist to treat insomnia disorder. Ann Neurol. 2020;87(3):347\u201356. https:\/\/doi.org\/10.1002\/ana.25680.","journal-title":"Ann Neurol"},{"key":"977_CR50","doi-asserted-by":"publisher","DOI":"10.1093\/sleep\/zsx142","author":"T-Y Chen","year":"2017","unstructured":"Chen T-Y, Lee S, Buxton OM. A greater extent of insomnia symptoms and physician-recommended sleep medication use predict fall risk in community-dwelling older adults. Sleep. 2017. https:\/\/doi.org\/10.1093\/sleep\/zsx142.","journal-title":"Sleep"},{"issue":"4","key":"977_CR51","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1177\/2042098613486829","volume":"4","author":"MR de Jong","year":"2013","unstructured":"de Jong MR, Van der Elst M, Hartholt KA. Drug-related falls in older patients: implicated drugs, consequences, and possible prevention strategies. Ther Adv Drug Saf. 2013;4(4):147\u201354. https:\/\/doi.org\/10.1177\/2042098613486829.","journal-title":"Ther Adv Drug Saf."},{"issue":"6","key":"977_CR52","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1111\/jcpt.13619","volume":"47","author":"R Sogawa","year":"2022","unstructured":"Sogawa R, Emoto A, Monji A, Miyamoto Y, Yukawa M, Murakawa-Hirachi T, et al. Association of orexin receptor antagonists with falls during hospitalization. J Clin Pharm Ther. 2022;47(6):809\u201313. https:\/\/doi.org\/10.1111\/jcpt.13619.","journal-title":"J Clin Pharm Ther"},{"issue":"1","key":"977_CR53","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1038\/s41386-020-00892-5","volume":"45","author":"M Ufer","year":"2020","unstructured":"Ufer M, Steiner MA, Post A, Dingemanse J, Toeroek M, Giusepponi M, et al. W150. Assessment of the abuse potential of daridorexant, a new dual orexin receptor antagonist for the treatment of insomnia disorder: data from preclinical and clinical studies. Neuropsychopharmacology. 2020;45(1):354. https:\/\/doi.org\/10.1038\/s41386-020-00892-5.","journal-title":"Neuropsychopharmacology"},{"issue":"3","key":"977_CR54","doi-asserted-by":"publisher","DOI":"10.1093\/sleep\/zsab224","volume":"45","author":"M Ufer","year":"2022","unstructured":"Ufer M, Kelsh D, Schoedel KA, Dingemanse J. Abuse potential assessment of the new dual orexin receptor antagonist daridorexant in recreational sedative drug users as compared to suvorexant and zolpidem. Sleep. 2022;45(3): zsab224. https:\/\/doi.org\/10.1093\/sleep\/zsab224.","journal-title":"Sleep"},{"issue":"9","key":"977_CR55","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1007\/s40266-018-0569-8","volume":"35","author":"VC Abad","year":"2018","unstructured":"Abad VC, Guilleminault C. Insomnia in elderly patients: recommendations for pharmacological management. Drugs Aging. 2018;35(9):791\u2013817. https:\/\/doi.org\/10.1007\/s40266-018-0569-8.","journal-title":"Drugs Aging"},{"issue":"4","key":"977_CR56","doi-asserted-by":"publisher","first-page":"254","DOI":"10.2174\/1389200220666190206141814","volume":"20","author":"C Muehlan","year":"2019","unstructured":"Muehlan C, Fischer H, Zimmer D, Aissaoui H, Grimont J, Boss C, et al. Metabolism of the dual orexin receptor antagonist ACT-541468, based on microtracer\/ accelerator mass spectrometry. Curr Drug Metab. 2019;20(4):254\u201365. https:\/\/doi.org\/10.2174\/1389200220666190206141814.","journal-title":"Curr Drug Metab"},{"issue":"2","key":"977_CR57","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1007\/s00228-018-2559-5","volume":"75","author":"ML Boof","year":"2019","unstructured":"Boof ML, Alatrach A, Ufer M, Dingemanse J. Interaction potential of the dual orexin receptor antagonist ACT-541468 with CYP3A4 and food: results from two interaction studies. Eur J Clin Pharmacol. 2019;75(2):195\u2013205. https:\/\/doi.org\/10.1007\/s00228-018-2559-5.","journal-title":"Eur J Clin Pharmacol"},{"issue":"2","key":"977_CR58","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1111\/bcp.15029","volume":"88","author":"M Gehin","year":"2022","unstructured":"Gehin M, Wierdak J, Sabattini G, Sidharta PN, Dingemanse J. Effect of gastric pH and of a moderate CYP3A4 inducer on the pharmacokinetics of daridorexant, a dual orexin receptor antagonist. Br J Clin Pharmacol. 2022;88(2):810\u20139. https:\/\/doi.org\/10.1111\/bcp.15029.","journal-title":"Br J Clin Pharmacol"},{"issue":"5","key":"977_CR59","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1093\/sleep\/34.5.601","volume":"34","author":"CM Morin","year":"2011","unstructured":"Morin CM, Belleville G, Belanger L, Ivers H. The Insomnia Severity Index: psychometric indicators to detect insomnia cases and evaluate treatment response. Sleep. 2011;34(5):601\u20138. https:\/\/doi.org\/10.1093\/sleep\/34.5.601.","journal-title":"Sleep"}],"container-title":["Drugs & Aging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-022-00977-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40266-022-00977-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-022-00977-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,11]],"date-time":"2022-10-11T00:24:10Z","timestamp":1665447850000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40266-022-00977-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,13]]},"references-count":59,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["977"],"URL":"https:\/\/doi.org\/10.1007\/s40266-022-00977-4","relation":{},"ISSN":["1170-229X","1179-1969"],"issn-type":[{"value":"1170-229X","type":"print"},{"value":"1179-1969","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,13]]},"assertion":[{"value":"6 September 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 September 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was supported by Idorsia Pharmaceuticals Ltd, Allschwil, Switzerland. Idorsia funded the medical writing support (manuscript preparation).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"IF reports consulting fees from Bayer, Bioproject, Hennig, Idorsia Pharmaceuticals, Jazz Pharmaceuticals, and STADA and speaker activity\/reimbursement from Hennig, Idorsia Pharmaceuticals and Medice. CLAB reports consultancy fees from Bioproject, Takeda and Jazz Pharmaceuticals during the conduct of the trials. DM has been a clinical investigator for Apnimed, Eisai, Idorsia Pharmaceuticals, Imbrium, Janssen, Jazz Pharmaceuticals, Merck, Sage, Takeda and Vanda. WVM reports scientific advisor fees from Idorsia Pharmaceuticals and Janssen, and royalties from Wolter Kluwer. DSK and SP are employees of Idorsia Pharmaceuticals. IDSIQ was developed by Buysse DJ, Thompson W, Scott J, Franzen PL, Germain A Hall M, Moul DE, Nofzinger EA and Kupfer DJ of the University of Pittsburgh and as amended by Idorsia Pharmaceuticals Ltd. IDSIQ\u00a9 2020, University of Pittsburg. All rights reserved. IDSIQ-14 derivative created 2020 by Idorsia Pharmaceuticals Ltd under license and distributed by Idorsia Pharmaceuticals Ltd under license.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study protocol was approved by the appropriate institutional review boards or independent ethics committees and the study was performed in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All patients provided written informed consent.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The study sponsor will receive requests for individual participant data that underlie the results reported in this article, after deidentification, from researchers who provide a methodologically sound proposal. Please direct any requests to medicalinformationus@idorsia.com.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"All authors were involved in the study conceptualisation. DSK and SP were involved in data curation. SP was involved in the formal analysis. SP, DSK and IF were involved in the methodology. DSK was involved in supervision. SP was involved in validation and visualisation. IF, DWM and CLAB were trial investigators or participated in the conduct of the study. SP and DSK verified the data. All authors had full access to the data, were involved with review and editing of the manuscript, approved the final version of the manuscript and had final responsibility for the decision to submit for publication and agreed to be accountable for the work.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}